Shots:
- Merck has reported global P-III (TroFuse-005) trial data assessing sac-TMT (4 mg/kg, Q2W) vs doxorubicin/paclitaxel in 776 pts with endometrial carcinoma & carcinosarcoma who have received prior Pt-based CT & anti-PD-1/anti-PD-L1 immunotherapy either together or separately
- Trial met its 1EP of improved OS & PFS in the above pts, plus it also reached its key 2EP of ORR; data will be presented at a future meeting & discussed with global regulatory authorities
- sac-TMT is being assessed as both monotx. & in combination with immunotherapies in the TroFuse clinical program, which consists of 17 ongoing global P-III trials across multiple tumor types, incl. 10 P-III trials in women’s cancers
Ref: Merck | Image: Merck |Press Release
Related News: Merck Initiates P-IIb/III (MALBEC) Trial of MK-8748 for Neovascular Age-Related Macular Degeneration
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
